Earnings Call · Q2 FY2023·2023-08-14

Q2 23EPS +14.29%·Rev n/aQ1 23EPS -14.29%·Rev n/aQ4 22EPS -10.34%·Rev n/aQ3 22EPS 0.00%·Rev n/a⚠ consensus missing

NRX Pharmaceuticals, Inc. NRXP

Matthew Duffy — Chief Business Officer

Steve Willard — Chief Executive Officer

Jonathan Javitt — Co-Founder

Seth Voorhees — Chief Financial Officer

+2.7%1d on move date+3.9% vs SPY3d+1.2%5d−3.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NRXP calls or request research access.

More NRXP calls Browse calls Request research access